Analyst Update: Oramed Pharma, Akamai, Barnes & Noble

Analysts adjusted their ratings on Oramed Pharmaceuticals, Inc. (ORMP), Akamai Technologies, Inc. (AKAM), and Barnes & Noble, Inc. (BKS)

Apr 13, 2015 at 11:20 AM
facebook twitter linkedin


Analysts are weighing in today on drugmaker Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), cloud concern Akamai Technologies, Inc. (NASDAQ:AKAM), and book retailer Barnes & Noble, Inc. (NYSE:BKS). Here's a quick look at today's brokerage notes on ORMP, AKAM, and BKS.

  • MLV started coverage on ORMP with a "buy" opinion, and lifted its price target by $3 to $30, sending the shares up 20% to hit $7.48. The lofty target represents a 301% premium to Oramed Pharmaceuticals, Inc.'s current perch, but is in line with the shares' recent price action, up 63.8% year-to-date. Elsewhere, sentiment in the options pits has been call-heavy, as ORMP's Schaeffer's put/call open interest ratio (SOIR) of 0.47 stands in the 34th percentile of its annual range. Said another way, short-term speculators have rarely been this call-skewed on the stock over the past year. Meanwhile, short sellers could be getting antsy, as these bearish bets represent more than four weeks' worth of pent-up buying demand, at ORMP's average pace of trading.

  • CLSA cut its price target on AKAM by $1 to $82 while reaffirming its "buy" opinion, yet the shares are 0.3% higher at $71.65. On the charts, Akamai Technologies, Inc. has been a technical juggernaut, with the shares up 35.3% year-over-year. However, traders have been favoring puts over calls more than usual in the options pits, as AKAM's 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.75 stands higher than 93% of all similar readings from the past year. Meanwhile, the brokerage bunch is mostly bullish on the equity, as 71% of covering analysts rate it a "strong buy," and AKAM's consensus 12-month price target of $73.95 sits in territory not charted in more than a decade.

  • The shares of BKS are 6.7% higher at $23.77, after Craig-Hallum initiated coverage on the security with a "buy" rating and a $36 price target -- a level not conquered since early 2008. Furthermore, today's bump pulls of the shares out of the red for 2015, now up 2.5% year-to-date. Calls have been prominent in the options pits, as Barnes & Noble, Inc.'s 50-day ISE/CBOE/PHLX call/put volume ratio of 4.83 reads in the 80th percentile of its annual range. However, not all analysts have boarded the bullish bandwagon: just one of four brokerage firms offers up a "strong buy" endorsement.
 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners